Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73595068" target="_blank" >RIV/61989592:15110/19:73595068 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.termedia.pl/Arthropathic-psoriasis-complicated-by-a-paradoxical-reaction-in-the-form-of-erythrodermic-psoriasis-following-adalimumab-and-by-an-allergic-reaction-following-infliximab-which-was-successfully-managed,7,37483,1,1.html" target="_blank" >https://www.termedia.pl/Arthropathic-psoriasis-complicated-by-a-paradoxical-reaction-in-the-form-of-erythrodermic-psoriasis-following-adalimumab-and-by-an-allergic-reaction-following-infliximab-which-was-successfully-managed,7,37483,1,1.html</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5114/ada.2019.87454" target="_blank" >10.5114/ada.2019.87454</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab

Popis výsledku v původním jazyce

Secukinumab, an IL 17R inhibitor, belongs to the new generation of biological agents used for therapy of severe forms of psoriasis. It was approved by the European Medicines Agency for the treatment of psoriasis on January 15th 2015. We describe the case of a young patient with a severe course of arthropathic psoriasis, in whom therapy was associated with a number of complications and whose condition was successfully managed only after several years once secukinumab had been started.

Název v anglickém jazyce

Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab

Popis výsledku anglicky

Secukinumab, an IL 17R inhibitor, belongs to the new generation of biological agents used for therapy of severe forms of psoriasis. It was approved by the European Medicines Agency for the treatment of psoriasis on January 15th 2015. We describe the case of a young patient with a severe course of arthropathic psoriasis, in whom therapy was associated with a number of complications and whose condition was successfully managed only after several years once secukinumab had been started.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Postepy Dermatologii I Alergologii

ISSN

1642-395X

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

3

Strana od-do

495-497

Kód UT WoS článku

000485142200020

EID výsledku v databázi Scopus

2-s2.0-85072193540